Core Points - Cibus, Inc. announced leadership changes as part of its succession planning strategy, with Rory Riggs resigning as CEO and Peter Beetham appointed as Interim CEO [1][2] - The Board of Directors will search for a permanent CEO, considering both internal and external candidates [2] - Rory Riggs will remain as Chairman of the Board and expressed confidence in the leadership team during the transition [3] Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies for royalties, addressing productivity and sustainability challenges in agriculture [4] - The company utilizes its proprietary Rapid Trait Development System™ (RTDS®) for gene editing, aiming to develop traits more efficiently than conventional breeding methods [4] - Cibus has a pipeline of five productivity traits, including weed management in rice and disease resistance, which are its near-term focus [4]

Core Insights - Cibus, Inc. has corrected its previously disclosed gene editing conversion rates for rice, stating that the rates of 10-25% have not been reconfirmed due to high variability in data from subsequent experiments [1] - The company continues to advance its oligonucleotide directed mutagenesis (ODM) technologies to improve editing conversion rates across its developed traits [1][2] - Cibus focuses on developing and licensing productivity traits for major global row crops, including canola, rice, and soybean, addressing significant agricultural challenges [3] Company Overview - Cibus is a technology company that develops and licenses gene-edited traits to seed companies for royalties, rather than being a seed company itself [3] - The company aims to tackle productivity and sustainability challenges in agriculture, with an estimated global economic cost of $300 billion annually due to diseases and pests [3] - Cibus has a pipeline of five productivity traits, focusing on weed management in rice, pod shatter reduction, and disease resistance [3] Technological Advancements - Cibus employs a standardized high throughput, semi-automated system known as the Rapid Trait Development System™ (RTDS) to meet customer needs for germplasm edits [2] - The company is optimistic about its technological and process advancements and looks forward to future achievements in trait development [2]

Core Insights - Totus Medicines has appointed Simon Harnest as Chief Financial Officer, a strategic move as the company advances its clinical-stage program following positive results from its Phase 1 study of TOS-358, a covalent PI3Kα inhibitor [1][2] Company Overview - Totus Medicines specializes in small molecule drug discovery and development, utilizing a novel DNA-encoded covalent library technology combined with AI/ML, enabling the screening of hundreds of millions of drug candidates against multiple targets simultaneously [4] - The company is currently developing TOS-358, a covalent PI3Kα inhibitor, which is in a Phase 1 clinical trial, and is also working on other covalent inhibitors and has a drug discovery partnership with Lilly [4] Leadership and Experience - Simon Harnest brings over 15 years of experience in the biotech sector, having previously served as Chief Investment Officer at Metagenomi, where he led capital raises and the IPO process, contributing to over $1 billion in equity raised [3] - Harnest's prior roles include directing the US IPO and capital markets strategy at Cellectis and key positions at Trout Group and Trout Capital, focusing on investor relations in the life sciences industry [3]

Core Insights - Cibus, Inc. is a leading agricultural biotechnology company specializing in gene editing technologies to develop plant traits in seeds [1][2] - The company will present at the Sidoti Micro Cap Conference on January 23, 2025, at 1:45 p.m. ET [2] - Cibus focuses on productivity traits for major global row crops, addressing challenges such as diseases and pests that cost the global economy approximately $300 billion annually [2] Company Overview - Cibus is not a seed company but a technology company that licenses traits to seed companies in exchange for royalties on seed sales [2] - The company has developed a pipeline of five productivity traits, including Pod Shatter Reduction, Sclerotinia resistance, and weed management [2] - Initial traits for Pod Shatter Reduction and weed management are in commercial development with leading seed companies like Nuseed Americas Inc. and Nutrien Ltd. [2] Technology and Innovation - Cibus is a technology leader in high throughput gene editing, allowing for the development and commercialization of plant traits at a fraction of the time and cost compared to conventional breeding [2] - The company’s other pipeline traits, including Sclerotinia resistance, are currently in advanced greenhouse and field trial stages [2]

Core Viewpoint - Cibus, Inc. has announced a securities purchase agreement to sell 9,040,000 shares of Class A Common Stock at a price of $2.50 per share, aiming to raise approximately $22.6 million for further development of its agricultural biotechnology pipeline and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants and warrants to purchase an aggregate of 9,040,000 shares of Class A Common Stock, with the warrants exercisable upon stockholder approval at a price of $2.50 per share [1]. - The gross proceeds from the offering are expected to be around $22.6 million before deducting fees and expenses, with the offering anticipated to close on or about January 24, 2025 [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [3]. Group 2: Investor Warrants - Certain investors in the offering hold outstanding warrants to purchase up to 1,198,040 shares of Class A Common Stock, with the exercise price being reduced from $10.00 to $2.50 per share [4]. - The threshold for the redemption provision of the Investor Warrants has been lowered to $5.00 per share, and the termination date has been extended to five years following the closing of the offering [4]. Group 3: Company Overview - Cibus is a leader in gene editing technology focused on developing productivity traits for major global row crops, addressing challenges such as diseases and pests that cost the global economy approximately $300 billion annually [7]. - The company is not a seed company but a technology company that licenses traits to seed companies in exchange for royalties on seed sales [7]. - Cibus has developed a pipeline of five productivity traits, with some traits already in commercial development with leading seed companies [8].

Core Viewpoint - Cibus, Inc. has announced a securities purchase agreement for the sale of 9,040,000 shares of Class A Common Stock at a price of $2.50 per share, aiming to raise approximately $22.6 million to fund its pipeline development and general corporate purposes [1][2]. Group 1: Offering Details - The offering includes 9,040,000 shares of Class A Common Stock and warrants to purchase an equal number of shares, priced at $2.50 per share [1]. - The gross proceeds from the offering are expected to be around $22.6 million before expenses, with the offering anticipated to close on or about January 24, 2025 [2]. - The warrants will be exercisable upon stockholder approval and will expire five years after approval [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for further development of the company's productivity traits pipeline and for working capital and general corporate purposes [2]. Group 3: Investor Warrants - Certain investors will have their existing warrants' exercise price reduced from $10.00 to $2.50 per share, with the threshold for redemption also adjusted to $5.00 per share [4]. - The amendments to the Investor Warrants will take effect upon stockholder approval [4]. Group 4: Company Overview - Cibus is a leader in agricultural biotechnology, focusing on gene editing technologies to develop plant traits for major crops like canola, corn, rice, soybean, and wheat [7]. - The company addresses significant agricultural challenges, with its technology enabling faster and more cost-effective trait development compared to traditional breeding methods [7]. - Cibus has a pipeline of five productivity traits, with some traits already in commercial development with leading seed companies [8].

Core Insights - Cibus has established production standards for its proprietary RTDS gene editing process, enabling the delivery of traits in a customer's elite germplasm in less than 12 months [1][2][3] - The company aims to industrialize plant breeding through a standardized, time-bound, and predictable process, which has significant implications for the development and commercialization of new traits [1][3][5] Gene Editing Advancements - Cibus has developed production standards for traits in Rice (herbicide tolerance HT1 and HT3) and Canola (pod shatter reduction and herbicide tolerance HT2), as well as advanced traits in Canola (Sclerotinia resistance) [2] - The company can edit a customer's elite germplasm and return it with specific edits within 12 months, showcasing the efficiency of its gene editing process [2][4] Technological Innovations - Cibus' patented ODM technology allows for multiple DNA edits in a single pass, significantly reducing the time required for trait development compared to traditional methods [5][6] - The gene editing conversion rates are between 10% to 25% in Rice and as high as 50% in Canola, indicating improved efficiency in developing complex traits [6] Strategic Focus - Cibus is not a seed company but a technology company that licenses traits to seed companies for royalties, focusing on productivity traits for major global row crops like canola, rice, and soybean [7] - The company has a current pipeline of five productivity traits, including important traits for weed management in Rice, Pod Shatter Reduction, and Sclerotinia resistance, which are its near-term focus [7]

Core Insights - Cibus has established production standards for its proprietary RTDS gene editing process, enabling the delivery of traits in a customer's elite germplasm in less than 12 months [1][2][3] - The company aims to industrialize plant breeding through a standardized, time-bound, and predictable gene editing process [3][5] - Cibus has made significant advancements in gene editing technology, including the ability to make multiple DNA edits in a single pass, which reduces the time required for trait development and commercialization [5][6] Gene Editing Developments - Cibus has developed production standards for traits in Rice (herbicide tolerance HT1 and HT3) and Canola (pod shatter reduction and herbicide tolerance HT2), as well as advanced traits in Canola (Sclerotinia resistance) [2] - The company achieved high editing rates in Soybean cells related to its HT2 trait, although it did not meet its goal of a fully operational soybean platform by the end of 2024 [4][6] - Cibus' gene editing conversion rates range from 10% to 25% in Rice and can be as high as 50% in Canola [6] Technological Advancements - The company's patented oligonucleotide directed mutagenesis (ODM) technology allows for complex edits in a single process, contrasting with traditional methods that require sequential processes [5][6] - Cibus' semi-automated gene editing production system is designed to enhance efficiency and quality control, which are critical for managing process time and product quality [3][6] Market Position and Strategy - Cibus is positioned as a technology company that develops and licenses plant traits to seed companies, focusing on productivity traits for major global row crops such as canola, rice, and soybean [7] - The company addresses significant agricultural challenges, with the United Nations estimating that diseases and pests cost the global economy approximately $300 billion annually [7] - Cibus aims to create a new class of plant trait products that are regulated similarly to naturally occurring traits, differentiating its products from transgenic plants and other GMOs [7]

Core Insights - Cibus, in collaboration with Albaugh and RTDC, is advancing the commercialization of its Clethodim-tolerant HT-3 rice trait, aimed at providing a new weed management solution for U.S. rice farmers [1][2][3] - The HT-3 trait is a significant breakthrough in herbicide tolerance, expected to be the first of several stacked traits for improved weed management in rice [2] - Cibus is currently working with four seed partners for the HT-3 trait, including two in the U.S. and two in South America, and is in discussions with major rice seed companies in Asia [2] Company Overview - Cibus is a technology company specializing in gene editing to develop and license plant traits, focusing on productivity traits for major global row crops such as rice, canola, and soybean [4] - The company aims to address critical productivity and sustainability challenges for farmers, with an estimated global economic cost of $300 billion annually due to diseases and pests [4] - Cibus has a pipeline of five productivity traits, including those for weed management in rice, pod shatter reduction, and disease resistance [4]

Core Insights - Cibus, in collaboration with Albaugh and RTDC, is advancing the commercialization of its Clethodim-tolerant HT-3 rice trait, aimed at providing a new weed management solution for U.S. rice farmers [1][2][3] - The HT-3 trait is a significant breakthrough in herbicide tolerance, expected to be the first of several stacked weed management traits for rice, with four current seed partners and discussions ongoing with major rice seed companies in Asia [2][3] Company Overview - Cibus is a technology company specializing in gene editing to develop and license plant traits, focusing on productivity traits for major global row crops like canola, rice, and soybean [4] - The company aims to address critical agricultural challenges, with a pipeline that includes five productivity traits, particularly in weed management for rice [4]